A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Bempedoic acid (Primary) ; Ezetimibe (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 06 Nov 2017 Status changed from recruiting to completed.
    • 08 Sep 2017 Primary endpoint has been met. (Percent change in low-density lipoprotein cholesterol (LDL-C)), accordign to an Esperion Therapeutics media release.
    • 08 Aug 2017 Results published in an Esperion Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top